Large Inflow of Money Witnessed in Taro Pharmaceutical Industries Ltd.

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) dropped by -0.06 or -0.08 points during the last session to $142.09 per share. One of the highlights of the day was the net money flow figure, which stood at $2.06 million even as the stock accepted $8.65 million in upticks but rejected $6.58 million in downticks. The up/down ratio for the last observation was a 1.31. The 1-week percentage change for the stock price is registered at 0.61%.


The stock has recorded a 20-day Moving Average of 0.6% and the 50-Day Moving Average is 1.6%. The company shares have dropped 1.58% in the past 52 Weeks. On December 28, 2015 The shares registered one year high of $157.99 and one year low was seen on February 11, 2016 at $122.99. The 50-day moving average is $140.16 and the 200 day moving average is recorded at $143.4. S&P 500 has rallied 1.93% during the last 52-weeks.

Taro Pharmaceutical Industries Ltd. (NYSE:TARO): During Tuesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $143.24 and $140.64 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $144.17. The buying momentum continued till the end and the stock did not give up its gains. It closed at $143.56, notching a gain of 0.98% for the day. The total traded volume was 329,248 . The stock had closed at $142.17 on the previous day.

Currently the company Insiders own 13.8% of Taro Pharmaceutical Industries Ltd. shares according to the proxy statements. Institutional Investors own 12.98% of Taro Pharmaceutical Industries Ltd. shares.

Taro Pharmaceutical Industries Ltd. (Taro) is a science-based pharmaceutical company. The Company develops, manufactures and markets prescription (Rx) and over-the-counter (OTC) pharmaceutical products, primarily in the United States, Canada and Israel. Taro also develops and manufactures active pharmaceutical ingredients (APIs), primarily for use in its finished dosage form products. The Companys primary areas of focus include semi-solids formulations, such as creams and ointments, and other dosage forms, such as liquids, capsules and tablets, primarily in the dermatological and topical, cardiovascular, neuropsychiatric and anti-inflammatory therapeutic categories. Taros owned product brands include Rokacet, Topicort, Etopan, Lustra and Ovide. Its other generic products include acetazolamide, amiodarone hydrochloride, ammonium lactate, calcipotriene, carbamazepine, cetirizine hydrochloride, ciclopirox olamine, clindamycin, clobetasol propionate and clomipramine hydrochloride.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.